Pacira reports Q2 2026 results, updates guidance after iovera° sale to Zimmer Biomet
Pacira closed its iovera° divestiture on July 31, advanced its PCRX-201 gene therapy program, and trimmed full-year revenue guidance to reflect the sale.
SEC filing
Latest
1 story